{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:19:17Z","timestamp":1794273557354,"version":"4.9.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The detection of antibodies targeting neuronal antigens is a keystone for the diagnosis of autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS). This study aimed to compare the performance of a commercial tissue-based immunofluorescence assay (cIFA) to that of an inhouse IFA (hIFA) for the screening of autoantibodies targeting neuronal surface proteins in the cerebrospinal fluid (CSF) and to compare the performance of commercial cell-based assays (cCBA) to that of in-house CBA (hCBA) in serum samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between March and June 2021, 2135 CSF samples and 524 serum samples from 2283 patients referred to the French Reference Center on PNS and AE were prospectively included. CSF samples were all tested using 3 different assays: cIFA, hIFA, and cCBA. Serum samples were all tested using at least 1 cCBA and 1 hCBA for the detection of the following autoantibodies: CASPR2, GABABR, and LGI1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results &amp;amp; Discussion<\/jats:title><jats:p>Among the 2135 CSF tested, 93 (4.4%) were positive using both cIFA and hIFA, 1 (0.05%) was positive using only cIFA, and 6 (0.3%) were positive using only hIFA. Among the double-positive samples, 37 (39.8%) were positive using cCBA for the following autoantibodies: anti-NMDAR (n=16), -LGI1 (n=8), -CASPR2 (n=7), -GABABR (n=5), and \u2013DPPX (n=1) autoantibodies. The remaining 56 (60.2%) double-positive samples were negative using cCBA and additional tests were performed to identify the autoantibodies according to the pattern observed on the IFA. The only sample positive using cIFA but negative using hIFA was positive for anti-LGI1 autoantibodies using cCBA. Among the 6 samples negative using cIFA but positive using hIFA, only one sample was positive with cCBA for anti-NMDAR autoantibodies. These data indicate that, in CSF, cIFA and hIFA performed similarly for the detection of autoantibodies targeting neuronal surface proteins.<\/jats:p><jats:p>Regarding serum samples, cCBA and hCBA were both positive in 3 patients for CASPR2, 4 patients for LGI1, and 1 patient for GABABR. A positive cCBA and negative hCBA was observed in 2 patients for LGI1 and 4 patients for GABABR. A lack of specificity of GABABR cCBA is suspected as CSF explorations were negative in 3 of these patients and none presented clinical features highly suggestive of AE.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1563877","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T10:19:26Z","timestamp":1744712366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of commercial and in-house tissue-based and cell-based assays for the detection of autoantibodies targeting neuronal surface proteins: a prospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"David","family":"Goncalves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Benaiteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Rogemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sterenn","family":"Closs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laurie","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroua","family":"Dhairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Villard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fabien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19\u221231","DOI":"10.1136\/practneurol-2021-003073","article-title":"Paraneoplastic neurological syndromes: a practical approach to diagnosis and management","volume":"22","author":"Binks","year":"2022","journal-title":"Pract Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"839\u221287","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"798\u2212813","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease","volume":"21","author":"Pr\u00fcss","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.673339","article-title":"Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management","volume":"12","author":"Sechi","year":"2021","journal-title":"Front Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1043723","article-title":"The study of neural antibodies in neurology: A practical summary","volume":"13","author":"Fern\u00e1ndez-Fournier","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2024.110746","article-title":"Autoimmune central nervous system disorders: Antibody testing and its clinical utility","volume":"126","author":"Gilligan","year":"2024","journal-title":"Clin Biochem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1212\/NXI.0000000000000701","article-title":"Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes","volume":"7","author":"D\u00e9chelotte","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.691536","article-title":"Limitations of a commercial assay as diagnostic test of autoimmune encephalitis","volume":"12","author":"Ruiz-Garc\u00eda","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1691\u2212701","DOI":"10.1007\/s00415-022-11523-y","article-title":"SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques","volume":"270","author":"Vabanesi","year":"2023","journal-title":"J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1069368","article-title":"The diagnosis of anti-LGI1 encephalitis varies with the type of immunodetection assay and sample examined","volume":"13","author":"Mu\u00f1oz-S\u00e1nchez","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"82\u221294","DOI":"10.1002\/ana.24189","article-title":"Seroprevalence of autoantibodies against brain antigens in health and disease: Brain-Targeting Autoantibodies","volume":"76","author":"Dahm","year":"2014","journal-title":"Ann Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1127","DOI":"10.1212\/NXI.0000000000001127","article-title":"Anti-NMDAR encephalitis in the Netherlands, focusing on late-onset patients and antibody test accuracy","volume":"9","author":"Bastiaansen","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e200318","DOI":"10.1212\/NXI.0000000000200318","article-title":"Autoimmune encephalitis and paraneoplastic neurologic syndromes: A nationwide study on epidemiology and antibody testing performance","volume":"11","author":"Kerstens","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B14","doi-asserted-by":"publisher","first-page":"79\u221292","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"391\u2212404","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1066830","article-title":"Neuronal surface antigen-specific immunostaining pattern on a rat brain immunohistochemistry in autoimmune encephalitis","volume":"13","author":"Nagata","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"30\u22129","DOI":"10.1001\/jamaneurol.2022.4251","article-title":"Autoimmune encephalitis misdiagnosis in adults","volume":"80","author":"Flanagan","year":"2023","journal-title":"JAMA Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"529\u221240","DOI":"10.1016\/S1474-4422(23)00083-2","article-title":"Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease","volume":"22","author":"Dalmau","year":"2023","journal-title":"Lancet Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01385","article-title":"Autoantibody diagnostics in neuroimmunology: experience from the 2018 italian neuroimmunology association external quality assessment program","volume":"10","author":"Gastaldi","year":"2020","journal-title":"Front Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1212\/NXI.0000000000000404","article-title":"Improving the antibody-based evaluation of autoimmune encephalitis","volume":"4","author":"McCracken","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B22","doi-asserted-by":"publisher","first-page":"840\u221251","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis. Ropper AH, \u00e9diteur","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"283\u221299","DOI":"10.1111\/imr.13405","article-title":"Antibodies in neurological diseases: Established, emerging, explorative","volume":"328","author":"Li","year":"2024","journal-title":"Immunol Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1563877\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T10:19:27Z","timestamp":1744712367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1563877\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2025.1563877"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1563877","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"article-number":"1563877"}}